A Phase 1 Single-Arm, Open-Label Study of CA-4948 in Combination with Azacitidine and Venetoclax in Acute Myeloid Leukemia Patients in Complete Response with Measurable Residual Disease.
A single-arm, open-label, phase 1 study of CA-4948 in combination with azacitidine Combination with azacitidine and venetoclax in patients with acute myeloid leukemia after complete response with measurable residual deficiency Residual disease.
